

April 30, 2015

ASX Announcement

Appendix 4C: Consolidated Statement of Cash Flows

Manalto Limited (ASX: MTL) (formerly Healthlinx Limited, ASX: HTX) ("Company") is pleased to present the attached Appendix 4C: Consolidated Statement of Cash Flows for the quarter ending March 31, 2015.

Key activities during the quarter included the completion of the merger of Healthlinx Limited ("Healthlinx") and Manalto, Inc. ("Manalto"), as described in the prospectus lodged 14 January 2015 ("Prospectus"). Specifically, on 11 March 2015 Healthlinx acquired 100% of Manalto, and the combined entity was renamed Manalto Limited. This is treated as a reverse acquisition because the substance of the transaction is such that the pre-existing shareholders of Manalto obtained substantial control of Healthlinx. Accordingly, the Statement of Cash Flows comprises the cash transactions for Manalto for the full quarter and year to date periods, and the cash transactions for Healthlinx from the date of acquisition forward.

The operations of the Company are centered in the United States including 100% of current employees, the heavy majority of operating cash flows, and the location of the primary business address. Accordingly, the Directors have elected to present financial information in US dollars. All financial figures in this document are denominated in US dollars except where explicitly denoted.

The Company ended the quarter with cash balances of \$3,177 thousand, an increase of \$3,152 thousand from the start of the quarter. Key one-time cash transactions within the quarter include:

- 1. Issuance of capital of \$4,591 thousand (\$6,000 thousand AUD) as described in the Prospectus, offset by cash outlays directly related to this capital issuance of \$767 thousand, for net cash proceeds of \$3,824 thousand.
- 2. Proceeds from borrowings of \$233 thousand, which included \$128 thousand in short-term loans which were repaid within the quarter, and \$99 thousand in convertible notes as described in the Prospectus which were converted to ordinary shares within the quarter.

Justyn Stedwell **Company Secretary**Manalto Limited

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Manalto Limited

ABN

88 098 640 352

Quarter ended ("current quarter")

March 31, 2015

Consolidated statement of cash flows

		Current	Year to date
Cash flows related to operating activities		quarter	(9 months)
		\$USD'000	\$USD'000
1.1	Receipts from customers	22	27
1.2	December for (a) stoff costs	(216)	(9(()
1.2	Payments for (a) staff costs	(316)	(866)
	(b) advertising and marketing	(22)	(63)
	(c) research and development	(19)	(32)
	(d) leased assets	` ,	` /
	(e) other working capital	(248)	(423)
1.3	Dividends received		
1.4	Interest and other items of a similar nature received		
1.5	Interest and other costs of finance paid	(7)	(26)
1.6	Income taxes paid		
1.7	Other (provide details if material)		
1	Net operating cash flows	(590)	(1,383)

⁺ See chapter 19 for defined terms.

		Current quarter	Year to date (9 months)
		\$USD'000	\$USD'000
1.8	Net operating cash flows (carried forward)	(590)	(1,383)
	Cook flows well-to data investing activities		
1.0	Cash flows related to investing activities		
1.9	Payment for acquisition of: (a) businesses (item 5)	(190)	(190)
	(b) equity investments	(190)	(190)
	(c) intellectual property		
	(d) physical non-current assets	(2)	(14)
	(e) other non-current assets	(3) (3)	0
1.10	Proceeds from disposal of:	(3)	U
1.10	(a) businesses (item 5)	10	10
	(b) equity investments	10	10
	(c) intellectual property		
	(d) physical non-current assets		
	(e) other non-current assets		1
	(c) called non carroin assets		-
1.11	Loans to other entities		(227)
1.12	Loans repaid by other entities		21
1.13	Other (provide details if material)		
	Net investing cash flows	(186)	(399)
1.14	Total operating and investing cash flows	(776)	(1,782)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc. *	3,824	3.824
1.16	Proceeds from sale of forfeited shares	3,021	3.021
1.17	Proceeds from borrowings	233	1,197
1.18	Repayment of borrowings	(129)	(129)
1.19	Dividends paid	,	, ,
1.20	Other (provide details if material)		
	Net financing cash flows	3,928	4,892
	Net increase (decrease) in cash held	3,152	3,110
1.21	Cash at beginning of quarter/year to date	225	276
1.22	Exchange rate adjustments to item 1.20	(1)	(10)
1.23	Cash at end of quarter	3,377	3,377

^{*} Comprised of issuance of capital of \$4,591 thousand (\$6,000 thousand AUD) as described in the Prospectus, offset by cash outlays directly related to this capital issuance of \$767 thousand.

⁺ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

		Current quarter \$USD'000
1.24	Aggregate amount of payments to the parties included in item 1.2	47
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Includes compensation to executive Director Anthony Owen

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Manalto Convertible Notes with a value of approximately \$1,555 thousand USD were converted to Manalto ordinary fully paid shares, as disclosed in the Prospectus lodged 14 January 2015.

The acquisition of Manalto, Inc..by Healthlinx Limited is accounted for under AASB 2 Share Based Payments whereby the non-cash consideration in a reverse acquisition represents a deemed issue of shares by the legal acquiree (Manalto), equivalent to the current shareholder interest in Healthlinx post the acquisition. The excess of the assessed value of the share based payment over the net assets has been expensed to the income statement as a listing fee. The \$10 thousand amount reported in line 1.10(a) reflects the cash acquired.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$USD'000	Amount used \$USD'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

⁺ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$USD'000	Previous quarter \$USD'000
4.1	Cash on hand and at bank	3,377	225
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
	Total: cash at end of quarter (item 1.23)	3,377	225

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a)) \$USD'000	Disposals (Item 1.10(a)) \$USD'000
5.1	Name of entity	Healthlinx Limited	N/A
5.2	Place of incorporation or registration	Australia	
5.3	Consideration for acquisition or disposal	846	
5.4	Total net assets	(347)	
5.5	Nature of business	Biotechnology	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Date: 30/4/15
Company secretary

Print name: Justyn Stedwell

⁺ See chapter 19 for defined terms.

Notes

AIUO BEN NEU OSIBÓ IO-

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
- 2. The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
- 3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

⁺ See chapter 19 for defined terms.